Los Angeles Capital Management LLC Purchases Shares of 23,433 Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Los Angeles Capital Management LLC purchased a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) during the third quarter, Holdings Channel.com reports. The firm purchased 23,433 shares of the biotechnology company’s stock, valued at approximately $544,000.

Several other hedge funds also recently modified their holdings of ARCT. Russell Investments Group Ltd. bought a new stake in Arcturus Therapeutics in the first quarter valued at $40,000. nVerses Capital LLC bought a new stake in Arcturus Therapeutics in the 3rd quarter valued at about $42,000. Quest Partners LLC raised its stake in Arcturus Therapeutics by 3,283.5% during the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after buying an additional 3,579 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Arcturus Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 2,038 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Arcturus Therapeutics in the second quarter valued at approximately $142,000. Institutional investors own 94.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Leerink Partners began coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They set an “outperform” rating and a $70.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research report on Friday, November 8th. Finally, Leerink Partnrs raised shares of Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Arcturus Therapeutics has a consensus rating of “Buy” and a consensus target price of $71.40.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock opened at $16.02 on Friday. The stock has a market cap of $433.93 million, a PE ratio of -7.22 and a beta of 2.64. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $14.93 and a fifty-two week high of $45.00. The firm’s 50-day simple moving average is $20.54 and its 200 day simple moving average is $23.97.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.44. The company had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same period in the prior year, the company posted ($0.61) earnings per share. As a group, analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.31 EPS for the current fiscal year.

Insider Buying and Selling at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 12,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the transaction, the chief operating officer now directly owns 435,334 shares of the company’s stock, valued at approximately $9,037,533.84. The trade was a 2.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 15.30% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.